www.genscript.com

Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects. The classical small molecule drug discovery strategies are inhibiting the biological function of proteins of interest, which either block the active pocket or change the protein conformation. However, the significant disadvantages such as limitations in target candidates, dose issues and quick resistance foundations, are calling for a more preferable therapy with fewer side effects. TPD, a strategy that utilizes the native protein homeostasis (or proteostasis) machinery to deplete proteins of interest (POI), represents a novel and promising therapeutic approach.

Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide. Natural antibodies are monospecific, while BsAbs recognize two different epitopes or antigens. This makes BsAbs hold great therapeutic promise for many diseases by linking an effector to a target cell, acting as ligands to two receptors or other mechanisms. However, the translation of these concepts into treatments is challenging. Without proper engineering, the side products from the light chain mispairing, heavy chain mispairing and BsAb fragments could lead to low purity, inability of repetition and toxicity. To solve the technical problems, advanced design strategies have been investigated, such as Knobs-into-holes, CrossMab technology, Duobody and common light chain. These technologies have greatly improved the development of bispecific antibodies, with many entities employing similar design approaches to develop their BsAb therapeutics. Do BsAb designs always work well as reported? What considerations should be taken for BsAb design? GenScript has production experience on thousands of BsAbs including about 80 BsAb formats and know well how the design affects the production. This webinar will focus on various strategies for BsAb design, the side products and how to get high purity BsAbs with different purification columns. Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.